Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • Featured Story

    One of the Telltale Signs Behind Risky Stocks

    Short-term corporate thinking has been blamed for many of America's economic ills.

    With little foresight beyond next year, management sometimes closes down plants and fudges accounting to make this year's earnings look better and boost the stock price.

    Often, it is simply because management is excessively rewarded by short-term incentives such as stock options.

    While investors might benefit from these shenanigans in the short-run, a new study points out the long-term effects are frequently negative.

    A new Harvard Business School study entitled "Short-termism, Investor Clientele and Firm Risk" has shown that short-termism is bad for investors increasing their risks without any corresponding increase in returns.

    In other words, risk and the short-term thinking usually go hand in hand.

    Breaking Down the Conference Call

    The study used a very interesting method to find out which companies are short-term oriented or more risky.

    To continue reading, please click here...
    Read More...
  • risky stocks 2012